Literature DB >> 11807789

Expression of uridine and thymidine phosphorylase genes in human breast carcinoma.

Atsuko Kanzaki1, Yuji Takebayashi, Hiroko Bando, James F Eliason, Shin-ichi Watanabe Si, Hitoshi Miyashita, Manabu Fukumoto, Masakazu Toi, Takafumi Uchida.   

Abstract

Uridine phosphorylase (UPase) and an angiogenic enzyme, thymidine phosphorylase (dThdPase) are involved in degradation of the pyrimidine nucleosides through phosphorolysis. The expression levels of UPase and dThdPase are higher in human solid tumors including breast carcinomas than in normal tissues. To clarify the correlation between the expression levels of UPase and dThdPase genes and the clinicopathological factors, mRNA levels of these enzymes were examined by RT-PCR in 43 breast carcinomas. UPase gene expression was not correlated with dThdPase gene expression (regression coefficient R = 0.032). Although the expression level of the dThdPase gene was correlated with angiogenesis, detected by immunostaining endothelial cells (R = 0.66), that of UPase gene was not (R = 0.044). These results suggest that UPase does not have a strong angiogenic activity. The UPase gene expression levels in tumors of patients who relapsed were significantly higher than in those from patients who did not (p = 0.039). Although the expression levels of neither UPase or dThdPase were associated with age, pT, pN, pM, estrogen or progesterone receptor positivity, the patients with the higher levels of UPase gene expression had worse survival (p = 0.0038) than those with lower levels. In contrast, the expression of dThdPase gene was not related to relapse or survival of these patients with breast carcinoma. Our findings suggest that the expression level of UPase gene may be an independent prognostic marker in human breast carcinoma. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11807789     DOI: 10.1002/ijc.10105

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Transcriptional analysis of pluripotency reveals the Hippo pathway as a barrier to reprogramming.

Authors:  Han Qin; Kathryn Blaschke; Grace Wei; Yuki Ohi; Laure Blouin; Zhongxia Qi; Jingwei Yu; Ru-Fang Yeh; Matthias Hebrok; Miguel Ramalho-Santos
Journal:  Hum Mol Genet       Date:  2012-01-27       Impact factor: 6.150

2.  Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity.

Authors:  Deliang Cao; Amy Ziemba; James McCabe; Ruilan Yan; Laxiang Wan; Bradford Kim; Michael Gach; Stuart Flynn; Giuseppe Pizzorno
Journal:  Mol Cancer Ther       Date:  2011-09-27       Impact factor: 6.261

3.  Crystallization of uridine phosphorylase from Shewanella oneidensis MR-1 in the laboratory and under microgravity and preliminary X-ray diffraction analysis.

Authors:  Tatyana N Safonova; Nadezhda N Mordkovich; Konstantin M Polyakov; Valentin A Manuvera; Vladimir P Veiko; Vladimir O Popov
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-10-30

4.  Vanadate as a new substrate for nucleoside phosphorylases.

Authors:  Alexey N Antipov; Natalya A Okorokova; Tatyana N Safonova; Vladimir P Veiko
Journal:  J Biol Inorg Chem       Date:  2022-01-30       Impact factor: 3.358

5.  Comparative Meta-Analysis of Transcriptomics Data during Cellular Senescence and In Vivo Tissue Ageing.

Authors:  Konstantinos Voutetakis; Aristotelis Chatziioannou; Efstathios S Gonos; Ioannis P Trougakos
Journal:  Oxid Med Cell Longev       Date:  2015-04-21       Impact factor: 6.543

6.  Uridine phosphorylase 1 is a novel immune-related target and predicts worse survival in brain glioma.

Authors:  Jin Wang; Shihai Xu; Wen Lv; Fei Shi; Shanshan Mei; Aijun Shan; Jianzhong Xu; Ying Yang
Journal:  Cancer Med       Date:  2020-06-24       Impact factor: 4.452

Review 7.  The dual role of thymidine phosphorylase in cancer development and chemotherapy.

Authors:  Annelies Bronckaers; Federico Gago; Jan Balzarini; Sandra Liekens
Journal:  Med Res Rev       Date:  2009-11       Impact factor: 12.944

Review 8.  Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism.

Authors:  Nikolaos Tsesmetzis; Cynthia B J Paulin; Sean G Rudd; Nikolas Herold
Journal:  Cancers (Basel)       Date:  2018-07-23       Impact factor: 6.639

Review 9.  Strained Conformations of Nucleosides in Active Sites of Nucleoside Phosphorylases.

Authors:  Irina A Il'icheva; Konstantin M Polyakov; Sergey N Mikhailov
Journal:  Biomolecules       Date:  2020-04-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.